T ype 1 diabetes is considered to be a chronic immunemediated disease characterized by selective loss of insulin-producing β cells in the pancreatic islets in genetically susceptible individuals. Overt clinical disease is preceded by an asymptomatic period of highly variable duration during which diabetes-associated autoantibodies appear in the peripheral circulation as markers of emerging β-cell autoimmunity.
1,2 Several disease-related autoantibodies predict clinical type 1 diabetes, including classic islet cell antibodies (ICAs), insulin autoantibodies (IAAs), and autoantibodies to glutamic acid decarboxylase (GAD); the tyrosine phosphatase-related insulinoma-associated 2 molecule (IA-2); and zinc transporter 8. 2 In natural history studies from infancy, positivity for 2 or more autoantibodies signals a risk of approximately 70% for the development of clinical diabetes over the subsequent 10 years. 3 The incidence of type 1 diabetes is increasing at an accelerating rate among children in North America and in most European countries. 4, 5 Accumulating evidence suggests that β-cell autoimmunity emerges early in life. 6, 7 Accordingly, any measure aimed at primary prevention of type 1 diabetes (ie, prevention of the initiation of the diabetic disease process) has to be initiated in infancy. In addition, there is a growing body of data suggesting that factors affecting the emergence of autoimmunity may be different from those associated with progression from autoimmunity to diabetes.
8,9
Some epidemiological and immunological studies suggest that exposure to complex foreign proteins in early infancy may increase the risk of β-cell autoimmunity and type 1 diabetes in genetically susceptible individuals, [10] [11] [12] although others do not. 13, 14 In our previous study, weaning to an extensively hydrolyzed casein formula did not decrease the cumulative incidence of diabetes-associated autoantibodies by 7 years of age in at-risk children. 15 This article reports on the intervention effect on diabetes incidence by 11.5 years of age in the TRIGR (Trial to Reduce Insulin-Dependent Diabetes Mellitus in the Genetically at Risk) Study.
Methods

Study Design
A randomized, double-blind study was conducted in 78 study centers from 15 countries as previously described. 16 The study protocol is available in Supplement 1. Newborn infants who had a first-degree relative with type 1 diabetes and defined human leukocyte antigen (HLA) genotypes were recruited between May 2002 and January 2007 and followed up until the youngest participant reached 10 years of age in February 2017. Randomization of the infants who met the inclusion criteria took place before birth or immediately after birth ( Figure 1 ). Randomization was stratified by study center, with a block size of 4. Written informed consent was obtained from the family before enrollment. The study was approved by the ethics committees of all participating centers.
Dietary Intervention
Infants were randomly assigned weaning to either the intervention or control formulas, which were produced specifically for this study. Randomization was carried out in each strata within 4 blocks. The intervention formula was an extensively hydrolyzed casein-based formula, while the control formula was composed of 80% intact cow's milk protein and 20% hydrolyzed milk protein and formulated so that the taste and smell would be indistinguishable from the intervention formula. Study formulas were prepared and coded with the use of 4 colors by Mead Johnson Nutritional and were blinded to all investigators except the data management unit. Newborn infants requiring supplemental feeding before randomization (eg, infants born at night or on weekends) received banked breast milk or Nutramigen, an extensively hydrolyzed casein-based formula.
Breastfeeding was practiced at the discretion of the participating mothers, and maternal diets were unmodified. Breastfeeding was encouraged and exceeded national averages in both groups. 17 The dietary intervention period lasted until the infant was at least 6 months of age and, if by that time the child had not received the study formula for at least 60 days, study formula feeding was continued until 60 days of study formula exposure was reached, but not beyond 8 months of age. Parents were asked not to feed the children any commercial or other baby foods containing bovine protein during the intervention period. Adherence to the protocol was monitored by means of regular family nutrition interviews (at the age of 0.5, 1, 2, 3, 4, 5, 6, 7, and 8 months) and by the analysis of cow's milk antibodies in serum samples.
HLA Genotyping
Cord blood or a heel stick blood sample collected on filter paper shortly after birth was immediately sent to the Turku (Europe and Australia) or Pittsburgh (North America) laboratories for HLA genotyping. HLA genotyping for the selected DQB1 and DQA1 alleles was performed using sequence-specific oligonucleotide hybridization, with quality control between the 2 laboratories carefully maintained. The following genotypes were regarded as eligible:
(1) HLA DQB1*02/DQB1*03:02 (high risk); (2) HLA DQB1*03:
02/x (x not DQB1*02, DQB1*03:01,orDQB1*06:02) (moderate risk); (3) HLA DQA1*05-DQB1*02/y (y not DQA1*02:01-DQB1*02, DQB1*03:01, DQB1*06:02,o rDQB1*06:03) (mild risk); and (4) HLA DQA1*03-DQB1*02/y (y not DQA1*02:01-DQB1*02, DQB1*03:01, DQB1*06:02,o rDQB1*06:03) (rare mild risk).
β-Cell Autoimmunity
ICAs were detected using indirect immunofluorescence. The other 3 autoantibodies were quantified with the use of specific radiobinding assays in the Scientific Laboratory, Children's Hospital, University of Helsinki, Helsinki, Finland, with cutoff limits for positivity of 2.5 JDF units for ICAs, 2.80 relative units (RU) for IAA, 5.36 RU for GAD autoantibodies, and 0.77 RU for IA-2 autoantibodies. 18 The disease sensitivity and specificity of the ICA assay were 100% and 98%, respectively, in the fourth round of the international workshops on standardization of the ICA assay. According to the Diabetes Autoantibody Standardization Program and the International Autoantibody Standardization Program workshop results in 2002-2016, the disease sensitivities of the IAA, GAD autoantibody, and IA-2 autoantibody radiobinding assays were 42% to 62%, 70% to 92%, and 62% to 80%, respectively. The corresponding disease specificities were 93% to 99%, 90% to 98%, and 93% to 100%, respectively.
Outcomes
The primary end point was the diagnosis of diabetes according to World Health Organization criteria. 19 According to those criteria, the diagnosis is based on (1) symptoms + a single random plasma glucose level of 200 mg/dL or greater (to convert to mmol/L, multiply by 0.0555) or (2) if no symptoms, the diagnosis requires a raised random plasma glucose reading of 200 mg/dL or greater on 2 occasions, a raised fasting plasma glucose reading of 126 mg/dL or greater, or a diabetic oral glucose tolerance test (OGTT, fasting venous plasma glucose ≥126 mg/dL and/or a 2-hour venous plasma glucose ≥200 mg/dL) on 2 occasions. OGTTs were performed by protocol on all study participants who had not been previously diagnosed at 6 and 10 years of age and at study end. Additional OGTTs were performed as clinically indicated. All diagnosed cases were centrally reviewed. d Per-protocol analysis included participants with exposure to the study formula for 60 days or longer and no exposure to nonallowed foods.
Statistical Analyses
The cumulative incidence of diabetes onset from the time of randomization within each group was estimated using a modified Kaplan-Meier diabetes-free survival function. The difference between groups in the cumulative incidence functions, and the associated hazard functions, was tested using the Mantel-log rank test on discrete time to type 1 diabetes (6-month intervals). The relative risk of diabetes onset between groups was estimated from the discrete Cox proportional hazard model. 20 The proportionality assumption of the Cox proportional hazard model was tested. First, the Schoenfeld residuals were examined to determine whether there was an association with time. Second, the interaction of parameters of interest and time were included in the models and tested for significance. For treatment and the variables used in the adjusted models, the null hypothesis of proportionality failed to be rejected. The analyses were adjusted for HLA risk, duration of breastfeeding, duration of study formula consumption, sex, and region, while treating study center as a random effect. The critical value for the test statistic (P = .047) and confidence intervals in this primary analysis were adjusted for multiple looks, which took place during the trial and were based on the Lan and DeMets 21 spending function. When comparing data between the 2 study groups, the t test was applied for normally distributed variables and the nonparametric Mann-Whitney U test for skewed variables. The effects of weaning to the casein hydrolysate vs conventional formula were tested using the intention-to-treat principle including all HLA-eligible participants who were randomized to a treatment group. Tests of significance reported herein were 2-tailed. Statistical analyses were performed using SAS version 9.4 (SAS Institute). No imputation for missing values was performed; rather, observations with relevant missing values were excluded from respective analyses. The analysis of diabetes risk was also performed according to treatment received (per-protocol analysis). Participants were included in this analysis if they had exposure to the study formula for 60 days or longer and were not exposed to nonallowed foods. This study was designed such that given a confidence level of 95%, an estimated cumulative incidence of diabetes of 7.6% by the age of 10 years in the control group and an expected dropout rate of 20% by 10 years and a frequency of 10% of exclusive breastfeeding (up to age of 6 months), the study would have 80% power to detect a 40% change in the end point. As a post hoc analysis, the hazard ratio of the treatment groups was also calculated after adjusting for the age at which multiple autoantibodies appeared as an exploratory analysis.
Results
Altogether, 2159 newborn infants (1021 female [47.3%]) with an eligible HLA genotype (41.9% of the genotyped infants) were randomized to the intervention study. Five hundred sixteen infants (23.9%) carried the high-risk HLA genotype; 953 (44.1%), moderate-risk genotypes; 668 (31.0%), mildrisk genotypes; and 22 (1.0%), the rare mild-risk genotype. The first-degree relative with type 1 diabetes was the mother in 1052 infants (48.8%), the father in 722 (33.4%), and a sibling in 308 (14.3%), and 77 participants (3.5%) had multiple affected relatives. The median follow-up time for the diagnosis of diabetes was 11.5 years (Q1-Q3, 10.2-12.8 years; mean, 11.0 years). Randomization resulted in 1081 infants in the casein hydrolysate group and 1078 in the control group. There were no differences in the demographics or the distribution of HLA genotypes between the 2 groups (Table 1) .
Study Intervention
Eighty percent of infants in the casein hydrolysate group and 80.9% in the control group were exposed to the study formula during the intervention period. The mean (SD) ages of the infants at the time of study formula introduction were 2.0 (2.3) months in the hydrolysate group and 1.8 (2.2) months in the control group (difference, 0.2 months [95% CI, 0-0.42]). The mean (SD) duration of study-formula feeding was 10.2 (9.3) weeks in the casein hydrolysate group and 11.7 (9.7) weeks in the control group (difference, 1.5 weeks [95% CI, 0.7-2.3]; P < .001). As previously reported, the analysis of cow's milk antibodies confirmed that the families adhered well to the dietary intervention, resulting in conspicuous differences in the antibody levels between the treatment groups.
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Progression to Diabetes
The median age at initial seroconversion was 1.6 years (Q1-Q3, 1.0-3.0 years) in the casein hydrolysate group among those who progressed to clinical diabetes, whereas it was 1.5 years (Q1-Q3, 1.0-3.0 years; P = .38) among the progressors in the control group. The mean duration from seroconversion to clinical diabetes was 4.1 years (median, 3.5 years [Q1-Q3, 1.4-6.6]) in the casein hydrolysate group and 3.9 years (median, 3.1 years [Q1-Q3, 1.1-6.2]) in the control group (difference, 0.2 years [95% CI, −0.8 to 1.1]; P = .76). The number of participants who were positive for each specific autoantibody during the preclinical period is shown in Table 1 . Five children (5.5%) in the casein hydrolysate group and 6 (7.3%) in the control group had no detectable autoantibodies before the diagnosis of diabetes (P = .62). At diagnosis, the number of autoantibody-negative participants had dropped to 4 (4.4%) and 5 (6.1%), respectively (difference, 1.7% [95% CI, −6.4% to 10.4%]).
Diabetes
During follow-up, diabetes developed in 91 children in the casein hydrolysate group (8.4%) and in 82 in the control Figure 2 ). The hazard ratio for type 1 diabetes adjusted for HLA risk group, duration of breastfeeding, duration of study formula consumption, sex, and region, while treating study center as a random effect, was 1.1 (95% CI, 0.8-1.5; P = .46). There was no significant difference in the median age at diagnosis between the 2 groups (6.0 years [Q1-Q3, 3.1-8.9] vs 5.8 years [Q1-Q3, 2.6-9.1]; P = .75; difference, 0.2 years [95% CI, −0.9 to 1.2]). About one-fourth of the cases in each group were diagnosed without clinical symptoms ( Table 2) . Five children (5.5%) in the casein hydrolysate group and 3 (3.7%) in the control group presented with diabetic ketoacidosis (difference, 1.8% [95% CI, −6.3% to 9.8%]; P = .57). Comparisons between the treatment groups within HLA risk groups, according to the relationship to the affected family member (father, mother, or sibling with diabetes), geographic region associated with the clinical site of enrollment, or sex were not statistically significant ( Table 3) . The prespecified per-protocol analysis was defined to include those who were not exposed to any nonallowed foods containing cow's milk and had exposure to study formula for at least 60 days. The hazard ratio for type 1 diabetes in this subpopulation (n = 1177), adjusted for HLA risk group, duration of breastfeeding, duration of study formula consumption, sex, and region, while treating study center as a random effect, was 1.1 (95% CI, 0.7-1.7; P = .63).
As noted previously, the 2 treatment groups did not differ according to the characteristics of participants who developed diabetes (Table 2) or when analyzed within prespecified subgroups ( Table 3) . As a post-hoc analysis, the hazard ratio of the treatment groups was estimated after adjusting for the age at which multiple autoantibodies appeared (median, 3.2 years [Q1-Q3, 1.6-6.3] in the casein hydrolysate group and 3.0 years [Q1-Q3, 1.5-6.1] in the control group; P = .42) with little effect on the overall results (hazard ratio, 0.95 [95% CI, 0.70-1.28]; P = .95). 
Adverse Events
The frequency of any infection was 0.90 events/year in the hydrolysate group and 0.93 events/year in the control group. The corresponding frequencies of upper respiratory infections were 0.48 and 0.50, respectively. The rate of other adverse events was of the same magnitude in the 2 groups (eTable in Supplement 2). Similar linear growth and weight gain were observed in both groups.
Discussion
In this international randomized trial in children with an HLA genotype conferring increased risk for type 1 diabetes and an affected first-degree relative, weaning to a highly hydrolyzed formula during infancy did not reduce the incidence of type 1 diabetes compared with cow's milk-based formula. This outcome is consistent with the report of this trial that showed no difference between the study groups in the appearance of islet autoantibodies, 15 but is not consistent with data from the pilot study, 22 which reported that weaning to an extensively hydrolyzed formula in infancy was associated with a decrease in the frequency of diseaseassociated autoantibodies by the age of 7.5 years. That study was conducted in 230 Finnish children, while the current trial included 2159 high-risk children from 15 different countries, most participants being from Canada, Finland, and the United States. The larger number of participants in this study provides substantially greater statistical power in a more heterogeneous study population compared with the pilot study and, therefore, provides a more definitive answer to whether weaning to an extensively hydrolyzed formula is protective of diabetes. Overall, 173 participants (8.0%) progressed to type 1 diabetes during the follow-up for 11.5 years. This is close to an expected rate of 7.5% by the age of 10 years in the control group, on which the sample size estimate was based. For unknown reasons, the rate of diabetes was higher, although not significantly so, among females compared with males in the casein hydrolysate group. About 49% of the participants had a mother affected by type 1 diabetes, while only around 35% of those who presented with clinical disease had an affected mother. This reflects the well-known fact that offspring of mothers with type 1 diabetes have a reduced disease risk compared with offspring of affected fathers.
23,24
Additional strengths of the current trial include a very high retention rate of participants and dietary adherence. The fact that the study was performed in 15 countries on 3 continents also supports the generalizability of the results. This study was planned to have 2 end points, namely (1) positivity for 2 autoantibodies by the age of 6 years and (2) clinical diabetes by the age of 10 years. While the previous report of this study showed no benefit in terms of a reduction in seroconversion to autoantibody positivity, 15 the follow-up of the trial participants to 10 to 14 years of age enabled the study to evaluate the possible effect of the treatment on progression from autoimmunity to diabetes. The study was not designed to test the effect of breastfeeding because random assignment of infants to breastfeeding or formula feeding was not considered ethical. However, 
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JAMA January 2, 2018 Volume 319, Number 1 (Reprinted) jama.com no effect of exclusive breastfeeding was seen on progression to seroconversion or diabetes. Some prospective studies assessing the associations between infant feeding patterns and the development of β-cell autoimmunity in children who are at genetic risk for type 1 diabetes have not observed any associations between the duration of either exclusive or total breastfeeding and β-cell autoimmunity. 11,12 However, a recently published study involving children from the general population showed that no breastfeeding was related to an increased risk of diabetes compared with infants with history of any breastfeeding.
25
The casein-based formula used as the intervention modality in this study was highly hydrolyzed and did not contain intact proteins. Less than 0.3% of the peptides had a molecular weight exceeding 2000 Da. Accordingly, the formula should be free of intact bovine insulin, which is present in cow's milk. 26 Vaarala et al 26 showed that infants fed a conventional cow's milk-based formula before the age of 3 months developed a strong immune response to bovine insulin, which differs from human insulin by 3 amino acids.
Infants developing early signs of β-cell autoimmunity lacked the capacity to mount oral tolerance to bovine insulin. It has been speculated that sustained bovine insulin immunity might contribute to prediabetes progression, as weaning to an insulin-free formula reduced the cumulative incidence of autoantibodies by more than half in young children at genetic risk for type 1 diabetes. 27 The current data do not, however, support the bovine insulin hypothesis. To our knowledge, this is the first trial to test with adequate power whether eliminating exposure to foreign intact protein in the infant diet could prevent type 1 diabetes in a genetically high-risk population. This trial suggests that cow's milk does not play a critical role in the development of type 1 diabetes.
Limitations
The results of this study are not directly generalizable to the background population because participants were selected based on a positive family history for type 1 diabetes and an HLA genotype conferring risk for type 1 diabetes. In addition, the outcome is not necessarily applicable to children with other HLA genotypes.
Conclusions
Among infants at risk for type 1 diabetes, weaning to a hydrolyzed formula compared with a conventional formula did not reduce the cumulative incidence of type 1 diabetes after a median follow-up for 11.5 years. These findings do not support a need to revise the current dietary recommendations for infants at increased risk for type 1 diabetes. 
RESEARCH DESIGN AND METHODS
12
This is a randomized double blinded intervention study using an intention to treat statistical analysis to 13 compare the incidence of predictive autoantibodies and clinical diabetes in the two treatment groups. 14
A. STUDY POPULATION 15
Newborn infants who have a first degree relative (FDR) with type 1 diabetes (i.e. a mother, father or full 16 sibling), and who meet the inclusion but not the exclusion criteria are recruited: 17 The sample size estimation presented in Table 1 is based on experiences from family studies analyzing the 38 occurrence of autoantibodies in siblings of children with type 1 diabetes or in offspring of affected parents and 39 progression to clinical disease in such young first-degree relatives. The data on the frequency of multiple (> 2) 40 autoantibodies by the age of 6 years and the cumulative incidence of type 1 diabetes by the age of 10 years are 41 based on 82 young siblings from the DiMe Study carrying increased genetic risk for type 1 diabetes as defined 42 according to the criteria in the Pilot-2 trial (106). 43 Nineteen out of 325 offspring (5.9%) with increased genetic risk according to the criteria used in the Pilot-2 44 trial tested positive for at least one autoantibody by the age of 2.4 years in the German BABYDIAB study 45 (107). Seventeen of these 19 subjects (89%) developed multiple autoantibodies during prospective 46 observation. Assuming a constant increase in autoantibody frequency from age 2 to age 6 years, the expected 47 cumulative incidence of at least one antibody would be 14.8% and that of at least two antibodies 13.0% by the 48 age of 6, which is well within the 95% CI of the observed frequency of 20.7% of multiple autoantibodies in 49 the young DiMe siblings. 50
The cumulative incidence of at least one autoantibody by the age of 4 years was 10.6% in siblings and 51 offspring of affected subjects in the DAISY study from Denver (108). The frequency reached 37.9% in those 52 carrying the DR3/4, DQB1*0302 combination. Published data are not available allowing an estimation of the 53 frequency of at least one or at least two autoantibodies in subjects with increased genetic risk as defined in the 54
Pilot-2 trial. Nevertheless a constant increase in the frequency of at least one autoantibody from age 4 to age 55 6 years, would result in an autoantibody prevalence of 15.9% by the age of 6 years in siblings and offspring 56 irrespective of HLA-defined genetic risk. The DiMe study was used for the power calculation as it includes 57 the largest long term follow-up of young relatives. 58
The estimation that 2032 infants should be randomized for the trial (Table 1) All statistical analyses will be based upon the total cohort of subjects randomized into the trial. Although data 95 on some subjects may be missing at points in time, all relevant data available from each subject will be 96 employed in the analyses. In all principal analyses, subjects will be included in the group to which they were 97 initially assigned and this assignment will not be altered based on a subject's adherence to the assigned 98 treatment program. Analyses of each outcome will include an assessment of possible differences among 99 clinical centers. Baseline variables that will be used in stratified analyses include gender, HLA risk category 100 and other prognostic characteristics. If differences in baseline characteristics are observed, analyses will be 101 conducted of the effects of the treatments on outcomes adjusting for the potential confounding effects of these 102 baseline characteristics. If only a few such baseline characteristics are identified, analyses will be conducted 103 stratifying for those characteristics. If any more than a few baseline characteristics are identified, because of 104 small sample size, it will be necessary that regression models be employed to adjust the treatment comparison 105 for the confounding effects of those characteristics. A number of subgroup analyses are planned to help 106 identify individuals more likely to benefit from, or to be harmed by, the treatment. In regard to treatment 107 effects, definition of such subgroups will rely on baseline data, not data measured after randomization. Such 108 subgroups might include: gender, gender of the relative with type 1 diabetes, HLA risk group and other 109 factors suspected to be associated with the event. Exploratory data derived through subgroup analyses will 110 serve primarily to generate new hypotheses for subsequent testing, and conclusions drawn from subgroup 111 hypotheses not explicitly stated before data analysis will have less credibility than those from hypotheses 112 stated in the protocol. For safety monitoring, the Data Management Unit also will perform any and all 113 analyses that are appropriate to identify subgroups that may be at significantly increased safety risk. The 114 Kaplan-Meier method will be used to construct survival curves and the logrank statistic used to compare 115 treatment arms with respect to time until the development of autoimmunity or type 1 diabetes. 116 We therefore aim to randomize 2032 infants with increased genetic risk as defined in the genetic screening 117 section (E). To achieve that number 4516 infants must be screened assuming a frequency of 45% of the 118 genotypes conferring increased risk. The observed prevalence of risk genotypes was 50% among the 471 119 infants screened for the Pilot-2 trial in Finland. An enrollment scheme for the trial proper is presented in 120 Figure 1 . This flow sheet indicates that the trial requires initial access to 5806 pregnancies. This should 121 provide at least 4936 families with consent to participate in the trial before the birth of the child provided that 122 the consent rate is 85%. With an exclusion rate of 8.5% after birth based on the exclusion criteria 123 approximately 4516 infants will be available for genetic screening. The observed exclusion rate in the Pilot-2 124 trial was 8.6%. 125 Infants will be recruited over a four-year period and the planned follow-up will be 6 years after the last infant 126 has been accrued for the antibody endpoint and 10 years after the last infant is accrued for the type 1 diabetes 127 end point. Thus, all subjects will have at least 10 years of follow-up. 128 To facilitate recruitment and to minimize any possibility of unintentional exposure to CM protein, every 145 attempt is made to identify eligible families before the child is born. Written consent is obtained at this time; 146 the child will participate after birth if he/she meets the inclusion but not the exclusion criteria. Experience gained in the Pilot-2 study of this project is utilized to optimize the efficacy of the recruitment in 157 the study proper (use of diabetes societies, information in mass media etc.). In that pilot study we also found 158 that weekly staff meetings and continuing recruitment during weekends and vacation periods substantially 159 raises recruitment efficiency. Leaflets, distributed to "candidate" mothers, describing the project can be very 160 helpful. 161
D. SUBJECT ALLOCATION 162
Randomization takes place before birth or immediately after the birth of the child. The research assistant or 163 investigator obtains the formula allocation code from the Data Management Unit (DMU) by completing the 164 Randomization Form electronically. Subjects who meet the inclusion and do not meet exclusion criteria are 165 randomized as follows: randomization in each strata will be within four blocks. Subjects will receive either the 166 test formula, casein hydrolysate (Nutramigen™, Mead Johnson Nutritionals), not containing antigenic CM 167 protein, or a CM protein containing control formula which has an addition (20 %) of Nutramigen, whenever 168 breast milk is not available. Any subject requiring supplemental feeding prior to randomization (e.g. infants 169 born at night or on weekends) is given banked breast milk or Nutramigen. The randomization code will be 170 kept by the manufacturer and it will be opened when the last recruited child has reached the age of 6 years. 171
Cord blood is obtained from newborn infants whenever possible or alternatively a heel prick is performed to 172 obtain capillary blood as soon as possible after birth, at the latest at the age of 7 days. to the 20.7% proportion given in Table 1 for the positivity of at least two autoantibodies by the age of 6 years. 208 The selected risk genotypes are present in 81.0% of Finnish children with type 1 diabetes and in 22.5% of the 209 background population; the higher frequency in familial cases confirms our earlier observations (4). We do 210 not have available data on familial cases and newborn infants with a FDR with type 1 diabetes in other 211 populations, but comparative analyses of genotype frequencies in patients with type 1 diabetes and healthy 212 controls indicate that the genotyping protocol would function with quite similar efficiency in various 213 populations to enrich high risk subjects for the study (Table 2) . Several published data also support this view, 214 although exact proportions cannot be deduced because of the lack of detailed genotype frequencies (5-7). 215 powder made by the same company plus casein hydrolysate powder in a 4:1 ratio designed to mask the flavor 224 and smell distinctions between the two study formulas. The casein hydrolysate has been shown to reduce 225 diabetes frequency in the NOD mouse (8) and BB (9) rat models. The Study Formula contains all the nutrients 226 infants need. Their nutritive value is analogous to the regular infant formulas used in the TRIGR countries. 227 The formula has four different code numbers and has been packed in four different colors -two colors for test 228 formula and two colors for control formula. The 4-color coding scheme has been extensively tested in 229 formula studies, it aids the blinding process, provides a hard control for randomization during data analysis, 230 and avoids accidental mis-shipments as the families recognize "their" color. Only Mead Johnson Nutritionals 231 knows which colors correspond to test and control formulas. Subjects are allocated to receive one color 232 formula, which is maintained throughout the study. Each center maintains a reserve supply of each "color" 233 formula and is responsible for ensuring that the home supplies of each participant are maintained. The 234 company provides the coded formulas free of charge, whereas the shipping costs are paid by the study grant. 235
G. IMPLEMENTATION OF INTERVENTION 236
All recruited mothers are encouraged to breast-feed; the newborn infants are randomized before birth or as 237 soon as possible after birth so that any elective formula supplementation or weaning by the mother will be 238 done with the appropriate study formula. The duration of the intervention will be until at least 6 months of 239 age. If the mother chooses to exclusively breastfeed up to the age of 6 months she is advised, thereafter, if 240 milk supplementation is needed, to give the study formula until the age of 8 months. Similarly, if exclusive BF 241 lasts for 5 months, the infant would receive study formula for 2 months until the age of 7 months. Infant 242 feeding practices are altered as little as possible by the trial. In particular, BF practice(s) is entirely at the 243 discretion of participating mothers. 244
Newborn infants, who fulfill the inclusion criteria and whose parents have given their consent, N 4516 GENOTYPING Risk genotypes : HLA-DQB1*02/0302 HLA-DQB1*0302/x (x DQB1*02, *0301, *0602) HLA-DQA1*05 -DQB1*02/y (y DQA1*0201 -DQB1*02, DQB1*0302, *0301, *0602, *0603) HLA-DQA1*03 -DQB1*02/y (y DQA1*0201 -DQB1*02, DQB1*0302, *0301, *0602, *0603) n 2032 The rationale for the 6-8 month intervention period is based on the following considerations: in early infancy 245 the child receives the major part of energy in liquid form, either as human milk or CM-based formula. The 246 period chosen provides a reasonable and practical safety margin over the 2-3 months "vulnerable" time when 247 the gut is permeable to proteins, as suggested in several epidemiological studies (reviewed in ref. 10). 248 249 Dietary advice is given by a member of the study team at the first contact with the family after randomization, 250 at the 2 week, 1, 2, 4 and 5 month telephone calls from the center to the mother, and at 7 and 8 months for 251 those infants who continue in the intervention beyond the age of 6 months, and at the 3 and 6 month visits. 252 The families receive both written and oral instructions about infant feeding during the intervention period. 253 Parents will be given a pamphlet which describes the sequence and amounts of food recommended at specific 254 ages, according to local guidelines. It is important to avoid any contamination of the dietary intervention 255 with sources of CM protein (including milk products, beef, and veal) contained in foods ingested by the infant. 256 Thus, parents are provided with a list of all solid foods giving choices of brand names which can be given to 257 the infant and which do not contain CM protein; they are also provided with a list of foods to be avoided, as 258 they contain CM protein. Monitoring of compliance and retention strategy 264 The diet of the infant and the compliance with the avoidance of CM proteins are assessed at the delivery 265 hospital by interview, by a telephone interview when the infant 2 week-old, 1, 2, 4, and 5 month-old, and by 266 an interview during the visits at the age of 3, 6 and 9 months. Those families, whose infants continue in the 267 intervention beyond the age of 6 months, are in addition interviewed by phone, when the infant is 7 and 268 8-month-old. The dietary interviews are similar at all stages. We ask the families about the age at the end of 269 exclusive and total breastfeeding. We have several questions on the use of Study Formula: Age when the 270 feeding was started and age when regular, daily use started, whether the infant receives Study Formula at the 271 time of the interview, how much Study Formula the infant is receiving per feeding, how much Study Formula 272 the family has available at home at the time of the interview, and whether they need more or not. In the 273 interview form we also have questions on the frequency of use of breast milk, Study Formula and other foods. 274 The frequency of use of foods to be avoided during the intervention period is also asked. The Study Centers 275 record the amount of Study Formula given to the family, and all the unused formula must be returned to the 276 local study center the clinical visit closest to the end of the intervention period (at the 6 or 9 month visit). 277 Compliance with the avoidance of CM proteins is also assessed by measuring antibody levels to CM proteins 278 from sera at 3 and 6 months, and the results are analyzed by the Data Safety and Monitoring Board. We do not 279 intend to employ serum titers of antibodies to CM proteins as a surrogate of islet cell damage. After the delivery medical and perinatal history of the infant and mother (including birth weight and 292 gestational age) and the results of the newborn physical examination are recorded on the case report forms. 293
Dietary information
Follow-up Period during and after Intervention 294
The subjects visit the research center or have a home visit at the age of 3, 6, 9, 12, 18 and 24 months, and at 3, Blood for serology (diabetes-associated autoantibodies and CM antibodies) is drawn after the application of an 300 analgesic ointment on the venipuncture site at the above mentioned visits and serum samples are stored 301
centrally. In addition, the 3 and 6 month serum samples are available for use in the assessment of dietary 302 compliance. All serum samples are aliquoted and stored at -70 C°. Local measurement of plasma glucose 303 and glycated hemoglobin takes place at 12, 18, 24 months, and 3, 4, 5, 6, 7, 8, 9 and 10 years. The specimens 304 for plasma glucose are preferentially taken 1-2 hours postprandially. If the glycated hemoglobin is higher than 305 the range, an OGTT may be required to confirm the diagnosis as below. An OGTT will be performed at the 306 age of 6 and 10 years in all study subjects. A heparin blood sample (3-5 ml blood depending on age) is 307 obtained at each sampling time for the isolation of mononuclear cells. 
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The major outcome for the first phase will be the frequency of type 1 diabetes-associated autoantibodies 315 and/or the development of clinical diabetes by the age of 6 years. The outcome of the second phase will be 316 the manifestation of diabetes by the age of 10 years. The manifest diabetes outcome is assessed as the 317 proportion of subjects in each group who develop type 1 diabetes, as well as age at diagnosis. These subjects 318 will be classified as having type 1 diabetes if they fulfill one of the following criteria: Accordingly a second OGTT should be performed, if the first one is diabetic. There should be an 331 interval of at least one week between these two OGTTs. 332
The diabetes-associated autoantibody data will be disclosed when the autoantibodies have been assayed after 333 the 6-year visit, and the family will be informed by the Study Center as soon as the autoantibody results have 334 become available. 335
I. METHODOLOGY TO BE APPLIED 336
Methodology for Genetic Screening 337
The procedures used for HLA-DQ typing were specifically developed for screening relevant DQB1 and 338 DQA1 alleles (11, 12 acknowledged expertise in the analysis of diabetes-associated autoantibodies. The laboratory will pay 358 particular attention to quality control procedures of the assays for autoantibodies. All samples are bar-coded, 359 and the analyses will be performed on a blinded basis. Samples from the same individual will, however, be 360 stored in such a way that they can be run in the same assay. Samples will be analyzed in three assay rounds, 361 the first including samples from birth up to the age of 2 or 3 years, the second samples from the age of 2 or 3 362 years up to the age of 6 or 7 years, and the third samples from the age of 6-7 years to 10 years. The analyses of the second hypothesis will use the time of diagnosis of manifest type 1 diabetes as the only 479 outcome measure. The dataset will thus be similar to that of a cohort study, and the statistical analyses will 480 be carried out using the proportional hazards regression model (24) including the milk exposure as the risk 481 factor and potential confounding factors a covariates in the model. Also time-dependent covariates can be 482 included to assess the effects of potential modifying factors. The adjusted relative risk of type 1 diabetes 483 between the two groups of milk exposure will be estimated. Also the adjusted incidence of the disease in the 484 two groups can be assessed. 485
M. INTERIM ANALYSIS 486
An interim analysis of autoantibodies and clinical diabetes will be performed repeatedly by the Data Safety 487 and Monitoring Board, beginning 2 years after the last subject is recruited, in order to ensure that an 488 unexpectedly large protective effect of the intervention will be detected early. Although the follow-up will be 489 continued, the code will be opened and the results published if either of these analyses reaches sufficient 490 statistical significance, as defined by the Data Safety and Monitoring Board. 491
N. ETHICAL ISSUES 492
Ethical approval has been obtained at each study center. Written informed consent is requested from the 493 parents. If, during the course of this study, an alternative strategy for diabetes prevention is proven to be 494 effective, then we will inform the families of this possibility and discuss, and likely offer its use in a rational 495 fashion. 496 Detailed HLA information will be released by qualified personnel only on the request by the parents. 497 The family will be informed by the Study Center as soon as the autoantibody results have become available 498 after the 6 year visit. 499
O. TRAINING, PROJECT PLANNING AND TIME TABLE 500
To achieve standardization in the implementation of the study protocol, a detailed training program for the 501 study personnel is essential. The national coordinators, nurse and nutrition coordinators participate at vital 502 training sessions in their respective regions. We will utilize the experience gained during the second pilot 503 study in training and informing the national investigators and their staff, when we expanded the study to 504 Sweden, Estonia and Hungary (investigators' meetings, site visits by project staff etc. -Investigators meeting at the end of the 5. year to evaluate the progress of the study 549
P. PUBLICATION POLICY 550
The publication policy follows the guidelines published in New England Journal of Medicine (25) 
Q. ORGANIZATION AND ADMINISTRATION OF TRIGR 553
The trial will be executed by a multinational consortium of clinical research groups, in two large regional 554 organizations. The scale of the study is dictated by the logistics of recruitment, the necessity of completion 555 within a reasonable period of time, and the need for ethnic diversity in the study populations. Based on the 556 successful development and execution of TRIGR pilot studies, the central coordinating center with the study 557 PI will continue to be located in Helsinki (Dr. M. Knip organization functions of the study will be carried out in Helsinki and Tampa. These functions include data 565 acquisition, processing and storage, randomization and protocol administration. Monitoring and budgetary 566 administration will be carried out by the three major regional coordinating centers. 567
The essential laboratory functions required for TRIGR will be conducted in three central internationally 568 recognized study laboratories 1. for determination of diabetes-related autoantibodies (Dr. M. Knip, Helsinki), 569 and 2. for determination of compliance through measurements of CM antibodies (Dr. E. Savilahti, Helsinki) 570 3. MHC typing with optimized turn around time for Europe will involve the laboratory in Turku, Finland (Dr. 571 J. Ilonen). These laboratories served the same functions in the human pilot studies. An experienced MHC 572 laboratory in Pittsburgh, PA (Dr. M. Trucco) has been added to serve the North American centers with rapid 573 turn around time. Pilot experiments have been performed to optimize tissue typing for the satellites. Dr. S.M. 574
Virtanen will be responsible for the analysis of dietary data. 575
Three regional fiscal units in Helsinki (Europe), London (Canada), and Pittsburgh (USA) will be responsible 576 for operations in these respective regions, and for acquisition and transfer of data to the DMU in Tampa,  577 Florida. However, for governance purposes North America and Europe constitute two governance regions. 578 Communication among participants in each region will be largely by electronic means, but group meetings 579 will be essential during the initiation of the study, and throughout the recruitment and treatment phase. 580 Special provision will be required for 581
Committees
582
The two Regional Executive Committees will maintain effective electronic communication among the regions, 583 with personal meetings of representatives as needed, through the TRIGR International Executive Committee 584 (IEC). This coordinating committee will be under the Chairmanship of the lead principal investigator or his 585 delegate, with the co-chairmanship of the national coordinators in Canada and United States or their delegates, 586 and with representation of the several constituencies in the study groups. 587
The Data Safety and Monitoring Board supervises the safety issues in the study, and performs the interim 588 analyses, described above. It also supervises compliance issues, like the interpretation of CM antibody 589 assays. 590
Communication
591
During randomization and recruitment, rapid communication between each center, the genetics laboratories 592 and the central randomization center is essential. This will be achieved by the development of an internet 593 website with Email and fax backup. Once established, this communication format will be used throughout 594 the study. 595 596 The study group members represent a versatile and high-standard expertise in the fields of pediatrics, pediatric 597 diabetology, infant nutrition, pediatric gastroenterology, neonatology, obstetrics, nutrition science, genetics, 598 immunology and epidemiology. Many members are internationally recognized experts in their fields related 599 to research on type 1 diabetes, particularly on the etiology, pathogenesis and prevention of the disease, and 600 they have published extensively on the prediction, prevention and etiology of type 1 diabetes. In addition, 601 most centers in all regions have had substantial clinical trial experience in diabetes. 602
Participating centers
R. ANCILLARY STUDIES OUTSIDE THE CORE PROTOCOL 603
The present core protocol deals with type 1 diabetes associated autoantibodies and/or manifest type 1 diabetes. 604 In addition we intend, with support from other sources (e.g. JDRF) carry out in certain centers mechanistic 605 studies, to learn more about the possible mechanisms of the casein hydrolysate effects. Below are listed a few 606 examples of such mechanistic studies: 607 The appearance and function of autoreactive T cells and their cytokine repertoires; 608 Studies on gut immunology and its possible aberrations in the development of type 1 diabetes; 609 The possible role of bovine insulin as a triggering nutritional antigen; 610 The possible effect of the intestinal bacterial flora on the diabetogenicity of some CM proteins; 611 The interaction of certain viruses (enteroviruses, rota) with CM proteins in the gut; and 612 613 -Tetramer studies of autoreactive T cell pools. 614
